Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Discontinued Operations (2016 - 2018)

Soleno Therapeutics (SLNO) has disclosed Cash from Discontinued Operations for 3 consecutive years, with 188000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Cash from Discontinued Operations rose 66.61% to 188000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was 1361000.0, a 55.1% increase, with the full-year FY2018 number at 1361000.0, up 55.1% from a year prior.
  • Cash from Discontinued Operations was 188000.0 for Q4 2018 at Soleno Therapeutics, up from 405000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 188000.0 in Q4 2018 to a low of 2783000.0 in Q3 2016.
  • A 3-year average of 855927.2 and a median of 648000.0 in 2017 define the central range for Cash from Discontinued Operations.
  • Peak YoY movement for Cash from Discontinued Operations: surged 73.66% in 2017, then soared 41.61% in 2018.
  • Soleno Therapeutics' Cash from Discontinued Operations stood at 1384272.0 in 2016, then skyrocketed by 59.33% to 563000.0 in 2017, then soared by 66.61% to 188000.0 in 2018.
  • Per Business Quant, the three most recent readings for SLNO's Cash from Discontinued Operations are 188000.0 (Q4 2018), 405000.0 (Q3 2018), and 281000.0 (Q2 2018).